Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

Exclusion Criteria

• •1. active brain metastases and meningeal metastasis
• •2. uncontrollable tumor-related pain
• •3. massive pleural effusion, peritoneal effusion or pericardial effusion which cannot be controlled by repeated drainage;
• •4. radiotherapy to lung that is \>30 Gy within 24 weeks before the first dose,
• •5. imaging (CT or MRI) showed that the tumor invading the large vessels
• •6. Known EGFR/ALK mutation.
• •7. subjects with any known or suspected autoimmune diseases
• •8. subjects with known or suspected interstitial pneumonia;
• •9. Subjects with severe cardiovascular and cerebrovascular diseases
• •10. arteriovenous thrombosis events, such as deep vein thrombosis and pulmonary embolism, occurred within 3 months;
• •11. female subjects who are pregnant or lactation or who plan to be pregnant during the study period;
• •12. positive HIV test;
• •13. active hepatitis B
• •14. evidence of active TB infection within 1 year before first dose;
• •15. severe infection occurred within 4 weeks before the first dose
• •16. patients with clinically significant bleeding symptoms or with obvious bleeding tendency in the first month
• •17. subjects who is on systemic immunogenic agents;
• •18. a history of severe allergic reactions to other monoclonal antibodies/fusion proteins;
• •19. History of severe allergic reactions to carboplatin or pemetrexed or their preventive drugs;